<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Paroxysmal hemicrania: Treatment and prognosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Paroxysmal hemicrania: Treatment and prognosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Paroxysmal hemicrania: Treatment and prognosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Manjit S Matharu, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna S Cohen, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jerry W Swanson, MD, MHPE</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 16, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The trigeminal autonomic cephalalgias (TACs) are a group of primary headache disorders characterized by unilateral trigeminal distribution pain that occurs in association with ipsilateral cranial autonomic features [<a href="#rid1">1,2</a>]. The TACs include cluster headache, paroxysmal hemicrania, short-lasting unilateral neuralgiform headache attacks, and hemicrania continua [<a href="#rid3">3</a>].</p><p>This topic will review the treatment and prognosis of paroxysmal hemicrania. Other clinical aspects of paroxysmal hemicrania are reviewed separately. (See  <a class="medical medical_review" href="/d/html/3334.html" rel="external">"Paroxysmal hemicrania: Clinical features and diagnosis"</a>.)</p><p>Other trigeminal autonomic cephalalgias are discussed elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3326.html" rel="external">"Cluster headache: Epidemiology, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/3351.html" rel="external">"Cluster headache: Treatment and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3336.html" rel="external">"Short-lasting unilateral neuralgiform headache attacks: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/3338.html" rel="external">"Short-lasting unilateral neuralgiform headache attacks: Treatment and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3342.html" rel="external">"Hemicrania continua"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">PHARMACOLOGIC TREATMENTS</span><span class="headingEndMark"> — </span>The treatment of paroxysmal hemicrania is entirely prophylactic, as attacks are too short and intense for any acute oral treatment to be effective. <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">Indomethacin</a> is the treatment of choice for adults and children with paroxysmal hemicrania. Because it is rare and because indomethacin is highly effective, there are no large prospective clinical trials evaluating therapy for paroxysmal hemicrania.</p><p>For patients who cannot tolerate <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a>, one faces a difficult challenge. No other drug is consistently effective in paroxysmal hemicrania. Alternative drug therapies that may be useful are reviewed below.</p><p class="headingAnchor" id="H3"><span class="h2">Indomethacin</span><span class="headingEndMark"> — </span>By definition, paroxysmal hemicrania responds completely to <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a>. (See  <a class="medical medical_review" href="/d/html/3334.html" rel="external">"Paroxysmal hemicrania: Clinical features and diagnosis", section on 'Diagnostic criteria'</a>.)</p><p>Evidence supporting the effectiveness of <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> comes mainly from observational case series [<a href="#rid4">4-7</a>]. In the two largest series, the following observations were reported:</p><p class="bulletIndent1"><span class="glyph">●</span>In a prospective study of 31 patients with paroxysmal hemicrania, 30 patients could tolerate <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a>, and all had a positive response [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study with data for <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> response in 40 patients diagnosed with chronic paroxysmal hemicrania, a consistent response to indomethacin was noted in 30 (75 percent). Of the 30 consistent responders, 24 had complete response, while 6 patients had a partial response. An inconsistent response was observed in 10 (25 percent) [<a href="#rid4">4</a>]. While patients with an inconsistent response did not meet strict diagnostic criteria for paroxysmal hemicrania, the investigators noted that all had a headache phenotype that best fit with paroxysmal hemicrania rather than cluster headache.</p><p></p><p>The existence of indomethacin-insensitive paroxysmal hemicrania is controversial. However, there are reports of patients who have clinical symptoms consistent with paroxysmal hemicrania yet do not respond to <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> [<a href="#rid4">4,8</a>].</p><p class="headingAnchor" id="H4"><span class="h3">Dosage and side effects</span><span class="headingEndMark"> — </span>The starting dose of <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> for adults and older adolescents (≥15 years of age) is 75 mg daily in three divided doses (ie, 25 mg three times a day). The indomethacin dose should be increased to 150 mg daily in three divided doses for 3 to 10 days if there is an incomplete response to the starting dose after 3 days. The dose should be further increased to 225 mg daily in three divided doses for 10 days for partial responders if the index of suspicion is high.</p><p>For children (≤14 years of age), the <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> dose is 1 to 2 mg/kg daily given in two divided doses [<a href="#rid9">9</a>].</p><p>The use of <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> to confirm the diagnosis of paroxysmal hemicrania is reviewed separately. (See  <a class="medical medical_review" href="/d/html/3334.html" rel="external">"Paroxysmal hemicrania: Clinical features and diagnosis", section on 'Indomethacin trial'</a>.)</p><p>Complete resolution of the headache is typically prompt, usually occurring within one to two days of initiating the effective <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> dose. In patients who do not respond to indomethacin, the diagnosis of paroxysmal hemicrania should be reconsidered.</p><p>The typical maintenance dose of <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> is 25 to 100 mg daily. However, the effective maintenance dose can vary between 12.5 and 300 mg daily, depending on individual response and the fluctuation in attack severity [<a href="#rid10">10</a>]. Hence, dosage adjustments may be necessary to address the clinical fluctuations seen in paroxysmal hemicrania.</p><p>Suspicion for a secondary cause of paroxysmal hemicrania should be raised in patients who need escalating doses or become refractory to <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> treatment. Similarly, underlying pathology may be present in patients who require continuous high doses of indomethacin [<a href="#rid11">11</a>]. In such cases, we recommend careful diagnostic evaluation (or re-evaluation) for secondary causes, including brain imaging. (See  <a class="medical medical_review" href="/d/html/3334.html" rel="external">"Paroxysmal hemicrania: Clinical features and diagnosis", section on 'Neuroimaging'</a> and  <a class="medical medical_review" href="/d/html/3334.html" rel="external">"Paroxysmal hemicrania: Clinical features and diagnosis", section on 'Secondary paroxysmal hemicrania'</a>.)</p><p>Most patients can expect sustained efficacy of <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> treatment without developing tachyphylaxis, though about one-quarter develop gastrointestinal side effects [<a href="#rid12">12</a>]. The most common serious side effect of indomethacin is the development of peptic ulcers. Measures to prevent gastrointestinal side effects include testing and treating for <em>Helicobacter pylori</em> and the use of gastroprotection with <a class="drug drug_general" data-topicid="9657" href="/d/drug information/9657.html" rel="external">misoprostol</a> or proton pump inhibitors. These issues are discussed separately. (See  <a class="medical medical_review" href="/d/html/35.html" rel="external">"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity"</a>.)</p><p><a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">Indomethacin</a> suppositories are occasionally helpful if gastric intolerance is a major problem or when high doses, such as 300 mg daily, are required.</p><p>Nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) such as <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> also have potentially important renal and cardiovascular effects. Renal adverse effects include acute renal failure due to renal vasoconstriction, worsening of underlying hypertension, and electrolyte and fluid abnormalities. Additionally, the risk of renal cell cancer may be increased. Cardiovascular effects include interference by some agents with the antiplatelet activity of <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a>, an effect on coronary risk, and worsening of heart failure. (See  <a class="medical medical_review" href="/d/html/7991.html" rel="external">"Nonselective NSAIDs: Overview of adverse effects"</a>.)</p><p class="headingAnchor" id="H5"><span class="h3">Indomethacin discontinuation</span><span class="headingEndMark"> — </span>Upon discontinuation of <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a>, symptoms of paroxysmal hemicrania usually reappear within 12 hours to 2 weeks. During active headache cycles, however, skipping or even delaying doses may result in the prompt reoccurrence of the headache [<a href="#rid5">5</a>].</p><p><a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">Indomethacin</a> withdrawal strategies differ for patients with episodic and chronic forms of paroxysmal hemicrania.</p><p class="bulletIndent1"><span class="glyph">●</span>In patients with episodic paroxysmal hemicrania, <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> should be given for slightly longer than the typical headache bout and then gradually tapered.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with chronic paroxysmal hemicrania, long-term treatment is usually necessary. However, long-lasting remissions have been reported in rare patients following cessation of <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a>. Thus, we suggest an indomethacin drug withdrawal trial at least once every six months for patients with chronic paroxysmal hemicrania. This should be done by gradually tapering the dose of indomethacin.</p><p></p><p class="headingAnchor" id="H7"><span class="h2">Alternative drug therapies</span><span class="headingEndMark"> — </span>Patients who cannot tolerate <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> face a difficult challenge, since no other drug is consistently effective in paroxysmal hemicrania. Alternative drug therapies that may have some benefit for paroxysmal hemicrania include NSAIDs other than indomethacin, calcium channel blockers, and several other agents.</p><p class="headingAnchor" id="H8"><span class="h3">Other nonsteroidal anti-inflammatory drugs</span><span class="headingEndMark"> — </span>Numerous other NSAIDs have been tried in paroxysmal hemicrania, but none show the consistent and exquisite response provided by <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a>. The NSAIDs that have been reported to be partially or completely effective, mainly in isolated cases, include <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> [<a href="#rid13">13-15</a>], <a class="drug drug_general" data-topicid="8547" href="/d/drug information/8547.html" rel="external">ibuprofen</a> [<a href="#rid15">15</a>], <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a> [<a href="#rid15">15-18</a>], <a class="drug drug_general" data-topicid="9348" href="/d/drug information/9348.html" rel="external">diclofenac</a> [<a href="#rid15">15,19</a>], <a class="drug drug_general" data-topicid="8590" href="/d/drug information/8590.html" rel="external">ketoprofen</a> [<a href="#rid13">13</a>], and <a class="drug drug_general" data-topicid="9781" href="/d/drug information/9781.html" rel="external">piroxicam</a> beta-cyclodextrin [<a href="#rid20">20</a>].</p><p>Limited success in the treatment of paroxysmal hemicrania has been reported with the cyclooxygenase-2 (COX-2) inhibitors rofecoxib [<a href="#rid21">21-23</a>], <a class="drug drug_general" data-topicid="8847" href="/d/drug information/8847.html" rel="external">celecoxib</a> [<a href="#rid21">21,24</a>], and etoricoxib [<a href="#rid25">25</a>]. However, prolonged use of these agents is associated with an increased risk of myocardial infarction and stroke. (See  <a class="medical medical_review" href="/d/html/7968.html" rel="external">"NSAIDs: Adverse cardiovascular effects"</a>.)</p><p class="headingAnchor" id="H9"><span class="h3">Calcium channel antagonists</span><span class="headingEndMark"> — </span>There are several case reports of patients with paroxysmal hemicrania who had a partial or complete response to <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> [<a href="#rid15">15,26-29</a>], and verapamil is generally considered the best alternative drug treatment to <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> for paroxysmal hemicrania [<a href="#rid30">30</a>]. A pooled analysis of 16 patients from two studies reported a responder rate of 44 percent for verapamil [<a href="#rid31">31</a>]. Other calcium channel antagonists that have been reported to be effective in paroxysmal hemicrania include <a class="drug drug_general" data-topicid="8869" href="/d/drug information/8869.html" rel="external">flunarizine</a> [<a href="#rid15">15,32</a>] and <a class="drug drug_general" data-topicid="9697" href="/d/drug information/9697.html" rel="external">nicardipine</a> [<a href="#rid32">32</a>].</p><p>Given these data, we suggest <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> for patients with paroxysmal hemicrania who are unable to tolerate <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a>. Similarly, we suggest verapamil for patients with a clinical phenotype of paroxysmal hemicrania who have an incomplete or poor response to an adequate trial of indomethacin. Verapamil is usually started at 160 to 240 mg daily in two divided doses. A lower starting dose of 80 mg daily in two divided doses is suggested for older adult patients and adults of small stature. The dose can be increased as needed and as tolerated up to 480 mg daily in three to four divided doses. Most responders require a dose of 240 to 320 mg daily.</p><p class="headingAnchor" id="H10"><span class="h3">Other medications</span><span class="headingEndMark"> — </span>Other drugs reported to be partially or completely effective in paroxysmal hemicrania, mainly in isolated cases, include <a class="drug drug_general" data-topicid="9268" href="/d/drug information/9268.html" rel="external">acetazolamide</a> [<a href="#rid33">33</a>], <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> [<a href="#rid13">13,17</a>], ergotamines [<a href="#rid13">13</a>], <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> [<a href="#rid13">13</a>], and <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a> [<a href="#rid34">34</a>].</p><p>Limited data suggest other agents such as <a class="drug drug_general" data-topicid="9968" href="/d/drug information/9968.html" rel="external">sumatriptan</a> and <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> are rarely effective [<a href="#rid15">15,31,35,36</a>].</p><p class="headingAnchor" id="H11812155"><span class="h2">Treatment approach for children</span><span class="headingEndMark"> — </span>As in adults, <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> is the treatment of choice for children and adolescents with paroxysmal hemicrania [<a href="#rid9">9</a>]. (See <a class="local">'Indomethacin'</a> above.)</p><p>For children who cannot tolerate <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a>, a number of second-line treatments have been tried; the list includes COX-2 inhibitors, calcium channel antagonists (eg, <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a>, <a class="drug drug_general" data-topicid="8869" href="/d/drug information/8869.html" rel="external">flunarizine</a>), <a class="drug drug_general" data-topicid="10006" href="/d/drug information/10006.html" rel="external">topiramate</a>, and greater occipital nerve blocks [<a href="#rid9">9</a>]. Some of these agents can be given in combination [<a href="#rid37">37</a>]. However, none are as effective as indomethacin.</p><p class="headingAnchor" id="H11"><span class="h1">INTERVENTIONAL THERAPIES FOR REFRACTORY CASES</span><span class="headingEndMark"> — </span>Alternative approaches for the treatment of paroxysmal hemicrania include local blockades, neurostimulation, and surgical procedures.</p><p class="headingAnchor" id="H12"><span class="h2">Local blockades</span><span class="headingEndMark"> — </span>Local anesthetic blockades of pericranial nerves, including the greater occipital nerve, supraorbital nerve, and lesser occipital nerve, have been generally ineffective for paroxysmal hemicrania, as have stellate ganglion blocks, sphenopalatine ganglion blocks, and cervical sympathetic blocks [<a href="#rid13">13,38</a>]. A prospective, open-label study of 119 patients with trigeminal autonomic cephalalgias (TACs) found that multiple cranial nerve blockade was associated with improvement in only 25 percent of patients with paroxysmal hemicrania, whereas the treatment was associated with improvement in 56 to 83 percent in patients with other TACs [<a href="#rid39">39</a>].</p><p>However, there are two reports of complete response with local blockades. One was a patient with episodic paroxysmal hemicrania who consistently showed a complete response to greater occipital nerve blockade with a combination of <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a> and <a class="drug drug_general" data-topicid="9639" href="/d/drug information/9639.html" rel="external">methylprednisolone</a> but not <a class="drug drug_general" data-topicid="9169" href="/d/drug information/9169.html" rel="external">bupivacaine</a> [<a href="#rid40">40</a>]. Another case report described complete response to repetitive sympathetic chain block with a combination of bupivacaine and methylprednisolone introduced onto the C7 transverse process but not with <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> placebo [<a href="#rid41">41</a>]. This patient subsequently had a stellate ganglionectomy (sympathectomy) that rendered him pain-free, though follow-up was limited to 15 months.</p><p class="headingAnchor" id="H1058603974"><span class="h2">Neurostimulation</span><span class="headingEndMark"> — </span>Retrospective case reports and observational studies have reported improvement of paroxysmal hemicrania in small numbers of patients treated with various neurostimulation techniques, including occipital nerve stimulation [<a href="#rid42">42</a>], percutaneous vagus nerve stimulation [<a href="#rid43">43,44</a>], and deep brain stimulation [<a href="#rid45">45</a>]. However, the actual benefit of each of these treatments should be considered unknown until more definitive evidence is available.</p><p class="headingAnchor" id="H13"><span class="h2">Invasive surgery</span><span class="headingEndMark"> — </span>Response to surgical decompression of the supraorbital, supratrochlear, trigeminal, or greater occipital nerves has been reported in a small case series [<a href="#rid46">46</a>]. Other invasive surgical procedures, including trigeminal sensory root section, infraorbital nerve section, superficial petrosal nerve section, and sphenopalatine ganglionectomy, have been ineffective [<a href="#rid13">13,41</a>].</p><p class="headingAnchor" id="H14"><span class="h1">NATURAL HISTORY AND PROGNOSIS</span><span class="headingEndMark"> — </span>Paroxysmal hemicrania is a rare syndrome, and there is a paucity of literature on its natural history and long-term prognosis. The available evidence suggests that it is a lifelong condition. Patients generally obtain sustained relief with <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> treatment. (See <a class="local">'Indomethacin'</a> above.)</p><p><a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">Indomethacin</a> does not seem to alter the condition in the long term, though a significant portion of patients can decrease the dose of indomethacin required to maintain a pain-free state.</p><p class="headingAnchor" id="H678085210"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/110285.html" rel="external">"Society guideline links: Migraine and other primary headache disorders"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">Indomethacin</a><strong> for initial preventive therapy </strong>– For adults and children with a paroxysmal hemicrania, we recommend treatment with indomethacin (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). By definition, paroxysmal hemicrania responds completely to indomethacin. (See <a class="local">'Indomethacin'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Dosing </strong>– The starting dose of <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> for adults is 75 mg daily in three divided doses. For those with a partial response to indomethacin, the dose may be increased to 150 mg daily in divided doses after three days and further increased to 225 mg daily in divided doses.</p><p></p><p class="bulletIndent2">For children (≤14 years of age), the <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> dose is 1 to 2 mg/kg daily given in two divided doses.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Duration of therapy </strong>– For patients with episodic paroxysmal hemicrania, <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> should be given for slightly longer than the typical headache bout and then gradually tapered. For patients with chronic paroxysmal hemicrania, we suggest an indomethacin drug withdrawal trial by gradual dose tapering at least once every six months.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adverse effects </strong>– The most common serious side effect of <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> is the development of peptic ulcers. Other adverse effects include acute renal failure due to renal vasoconstriction, worsening of underlying hypertension, worsening of heart failure, and electrolyte and fluid abnormalities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alternative medications </strong>– For patients with paroxysmal hemicrania who are unable to tolerate <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> and for patients with a clinical phenotype of paroxysmal hemicrania who have an incomplete or poor response to an adequate trial of indomethacin, we suggest treatment with <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Calcium channel antagonists'</a> above.)</p><p></p><p class="bulletIndent1">Reasonable alternatives include <a class="drug drug_general" data-topicid="8907" href="/d/drug information/8907.html" rel="external">aspirin</a> and other nonsteroidal anti-inflammatory drugs (NSAIDs), such as <a class="drug drug_general" data-topicid="9682" href="/d/drug information/9682.html" rel="external">naproxen</a> and <a class="drug drug_general" data-topicid="9348" href="/d/drug information/9348.html" rel="external">diclofenac</a>. (See <a class="local">'Other nonsteroidal anti-inflammatory drugs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Invasive procedures </strong>– With the exception of isolated case reports, local anesthetic blockades of pericranial nerves and invasive surgical procedures have been generally ineffective for the treatment of paroxysmal hemicrania. (See <a class="local">'Interventional therapies for refractory cases'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis </strong>– The available evidence suggests that paroxysmal hemicrania is a lifelong condition. Patients generally obtain sustained relief with <a class="drug drug_general" data-topicid="8559" href="/d/drug information/8559.html" rel="external">indomethacin</a> treatment. (See <a class="local">'Natural history and prognosis'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Goadsby PJ, Lipton RB. A review of paroxysmal hemicranias, SUNCT syndrome and other short-lasting headaches with autonomic feature, including new cases. Brain 1997; 120 ( Pt 1):193.</a></li><li><a class="nounderline abstract_t">Goadsby PJ. Trigeminal autonomic cephalalgias. Pathophysiology and classification. Rev Neurol (Paris) 2005; 161:692.</a></li><li><a class="nounderline abstract_t">Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38:1.</a></li><li><a class="nounderline abstract_t">Boes CJ, Dodick DW. Refining the clinical spectrum of chronic paroxysmal hemicrania: a review of 74 patients. Headache 2002; 42:699.</a></li><li><a class="nounderline abstract_t">Sjaastad O, Apfelbaum R, Caskey W, et al. Chronic paroxysmal hemicrania (CPH). The clinical manifestations. A review. Ups J Med Sci Suppl 1980; 31:27.</a></li><li><a class="nounderline abstract_t">Matharu MS, Cohen AS, Frackowiak RS, Goadsby PJ. Posterior hypothalamic activation in paroxysmal hemicrania. Ann Neurol 2006; 59:535.</a></li><li><a class="nounderline abstract_t">Cittadini E, Matharu MS, Goadsby PJ. Paroxysmal hemicrania: a prospective clinical study of 31 cases. Brain 2008; 131:1142.</a></li><li><a class="nounderline abstract_t">Fuad F, Jones NS. Paroxysmal hemicrania and cluster headache: two discrete entities or is there an overlap? Clin Otolaryngol Allied Sci 2002; 27:472.</a></li><li><a class="nounderline abstract_t">Lambru G, Matharu M. Management of trigeminal autonomic cephalalgias in children and adolescents. Curr Pain Headache Rep 2013; 17:323.</a></li><li class="breakAll">Sjaastad O. Chronic paroxysmal hemicrania. In: Handbook of Clinical Neurology, Vinken PJ, Bruyn GW, Klawans HL, Rose FC (Eds), Elsevier Science, 1986. Vol 48, p.257.</li><li><a class="nounderline abstract_t">Sjaastad O, Stovner LJ, Stolt-Nielsen A, et al. CPH and hemicrania continua: requirements of high indomethacin dosages--an ominous sign? Headache 1995; 35:363.</a></li><li><a class="nounderline abstract_t">Pareja JA, Caminero AB, Franco E, et al. Dose, efficacy and tolerability of long-term indomethacin treatment of chronic paroxysmal hemicrania and hemicrania continua. Cephalalgia 2001; 21:906.</a></li><li><a class="nounderline abstract_t">Antonaci F, Sjaastad O. Chronic paroxysmal hemicrania (CPH): a review of the clinical manifestations. Headache 1989; 29:648.</a></li><li><a class="nounderline abstract_t">Kudrow DB, Kudrow L. Successful aspirin prophylaxis in a child with chronic paroxysmal hemicrania. Headache 1989; 29:280.</a></li><li><a class="nounderline abstract_t">Evers S, Husstedt IW. Alternatives in drug treatment of chronic paroxysmal hemicrania. Headache 1996; 36:429.</a></li><li><a class="nounderline abstract_t">Mateo I, Pascual J. Coexistence of chronic paroxysmal hemicrania and benign cough headache. Headache 1999; 39:437.</a></li><li><a class="nounderline abstract_t">Hannerz J, Ericson K, Bergstrand G. Chronic paroxysmal hemicrania: orbital phlebography and steroid treatment. A case report. Cephalalgia 1987; 7:189.</a></li><li><a class="nounderline abstract_t">Durko A, Klimek A. Naproxen in the treatment of chronic paroxysmal hemicrania. Cephalalgia 1987; 7:361.</a></li><li><a class="nounderline abstract_t">Pradalier A, Dry J. [Chronic paroxysmal hemicrania. Treatment with indomethacin and diclofenac]. Therapie 1984; 39:185.</a></li><li><a class="nounderline abstract_t">Sjaastad O, Antonaci F. A piroxicam derivative partly effective in chronic paroxysmal hemicrania and hemicrania continua. Headache 1995; 35:549.</a></li><li><a class="nounderline abstract_t">Siow HC. Seasonal episodic paroxysmal hemicrania responding to cyclooxygenase-2 inhibitors. Cephalalgia 2004; 24:414.</a></li><li><a class="nounderline abstract_t">Chakravarty A, Mukherjee A, Roy D. Trigeminal autonomic cephalgias and variants: clinical profile in Indian patients. Cephalalgia 2004; 24:859.</a></li><li><a class="nounderline abstract_t">Lisotto C, Maggioni F, Mainardi F, Zanchin G. Rofecoxib for the treatment of chronic paroxysmal hemicrania. Cephalalgia 2003; 23:318.</a></li><li><a class="nounderline abstract_t">Mathew NT, Kailasam J, Fischer A. Responsiveness to celecoxib in chronic paroxysmal hemicrania. Neurology 2000; 55:316.</a></li><li><a class="nounderline abstract_t">Farag M, Bahra A. Etoricoxib and celecoxib sensitive indomethacin-responsive headache disorders. Headache 2022; 62:383.</a></li><li><a class="nounderline abstract_t">Zidverc-Trajkovic J, Pavlovic AM, Mijajlovic M, et al. Cluster headache and paroxysmal hemicrania: differential diagnosis. Cephalalgia 2005; 25:244.</a></li><li><a class="nounderline abstract_t">de Almeida DB, Cunali PA, Santos HL, et al. Chronic paroxysmal hemicrania in early childhood: case report. Cephalalgia 2004; 24:608.</a></li><li><a class="nounderline abstract_t">Schlake HP, Böttger IG, Grotemeyer KH, et al. Single photon emission computed tomography (SPECT) with 99mTc-HMPAO (hexamethyl propylenamino oxime) in chronic paroxysmal hemicrania--a case report. Cephalalgia 1990; 10:311.</a></li><li><a class="nounderline abstract_t">Shabbir N, McAbee G. Adolescent chronic paroxysmal hemicrania responsive to verapamil monotherapy. Headache 1994; 34:209.</a></li><li><a class="nounderline abstract_t">May A, Leone M, Afra J, et al. EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. Eur J Neurol 2006; 13:1066.</a></li><li><a class="nounderline abstract_t">Stubberud A, Tronvik E, Matharu M. Treatment of SUNCT/SUNA, Paroxysmal Hemicrania, and Hemicrania Continua: An Update Including Single-Arm Meta-analyses. Curr Treat Options Neurol 2020; 11:42.</a></li><li><a class="nounderline abstract_t">Coria F, Claveria LE, Jimenez-Jimenez FJ, de Seijas EV. Episodic paroxysmal hemicrania responsive to calcium channel blockers. J Neurol Neurosurg Psychiatry 1992; 55:166.</a></li><li><a class="nounderline abstract_t">Warner JS, Wamil AW, McLean MJ. Acetazolamide for the treatment of chronic paroxysmal hemicrania. Headache 1994; 34:597.</a></li><li><a class="nounderline abstract_t">Cohen AS, Goadsby PJ. Paroxysmal hemicrania responding to topiramate. J Neurol Neurosurg Psychiatry 2007; 78:96.</a></li><li><a class="nounderline abstract_t">Pascual J, Quijano J. A case of chronic paroxysmal hemicrania responding to subcutaneous sumatriptan. J Neurol Neurosurg Psychiatry 1998; 65:407.</a></li><li><a class="nounderline abstract_t">Baraldi C, Pellesi L, Guerzoni S, et al. Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal. J Headache Pain 2017; 18:71.</a></li><li><a class="nounderline abstract_t">Bemanalizadeh M, Baghaei Oskouei H, Hadizadeh A, et al. Paroxysmal hemicrania in children and adolescents: A systematic review. Headache 2022; 62:952.</a></li><li><a class="nounderline abstract_t">Antonaci F, Pareja JA, Caminero AB, Sjaastad O. Chronic paroxysmal hemicrania and hemicrania continua: anaesthetic blockades of pericranial nerves. Funct Neurol 1997; 12:11.</a></li><li><a class="nounderline abstract_t">Miller S, Lagrata S, Matharu M. Multiple cranial nerve blocks for the transitional treatment of chronic headaches. Cephalalgia 2019; 39:1488.</a></li><li><a class="nounderline abstract_t">Rossi P, Di Lorenzo G, Faroni J, Sauli E. Seasonal, extratrigeminal, episodic paroxysmal hemicrania successfully treated with single suboccipital steroid injections. Eur J Neurol 2005; 12:903.</a></li><li><a class="nounderline abstract_t">Albertyn J, Barry R, Odendaal CL. Cluster headache and the sympathetic nerve. Headache 2004; 44:183.</a></li><li><a class="nounderline abstract_t">Miller S, Lagrata S, Watkins L, Matharu M. Occipital Nerve Stimulation for Medically Refractory Chronic Paroxysmal Hemicrania. Headache 2017; 57:1610.</a></li><li><a class="nounderline abstract_t">Tso AR, Marin J, Goadsby PJ. Noninvasive Vagus Nerve Stimulation for Treatment of Indomethacin-Sensitive Headaches. JAMA Neurol 2017; 74:1266.</a></li><li><a class="nounderline abstract_t">Kamourieh S, Lagrata S, Matharu MS. Non-invasive vagus nerve stimulation is beneficial in chronic paroxysmal hemicrania. J Neurol Neurosurg Psychiatry 2019; 90:1072.</a></li><li><a class="nounderline abstract_t">Walcott BP, Bamber NI, Anderson DE. Successful treatment of chronic paroxysmal hemicrania with posterior hypothalamic stimulation: technical case report. Neurosurgery 2009; 65:E997; discussion E997.</a></li><li><a class="nounderline abstract_t">Togha M, Totonchi A, Molaei H, Ansari H. The Promising Effect of Nerve Decompression in Trigeminal Autonomic Cephalalgias: Report of Case Series. Front Neurol 2021; 12:678749.</a></li></ol></div><div id="topicVersionRevision">Topic 3335 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9055807" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : A review of paroxysmal hemicranias, SUNCT syndrome and other short-lasting headaches with autonomic feature, including new cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16141962" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Trigeminal autonomic cephalalgias. Pathophysiology and classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29368949" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12390632" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Refining the clinical spectrum of chronic paroxysmal hemicrania: a review of 74 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6935856" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Chronic paroxysmal hemicrania (CPH). The clinical manifestations. A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16489610" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Posterior hypothalamic activation in paroxysmal hemicrania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18252775" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Paroxysmal hemicrania: a prospective clinical study of 31 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12472514" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Paroxysmal hemicrania and cluster headache: two discrete entities or is there an overlap?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23475698" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Management of trigeminal autonomic cephalalgias in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23475698" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Management of trigeminal autonomic cephalalgias in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7635724" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : CPH and hemicrania continua: requirements of high indomethacin dosages--an ominous sign?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11903285" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Dose, efficacy and tolerability of long-term indomethacin treatment of chronic paroxysmal hemicrania and hemicrania continua.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2693408" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Chronic paroxysmal hemicrania (CPH): a review of the clinical manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2745065" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Successful aspirin prophylaxis in a child with chronic paroxysmal hemicrania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8783475" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Alternatives in drug treatment of chronic paroxysmal hemicrania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11279922" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Coexistence of chronic paroxysmal hemicrania and benign cough headache.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3652201" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Chronic paroxysmal hemicrania: orbital phlebography and steroid treatment. A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Naproxen in the treatment of chronic paroxysmal hemicrania</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6729768" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : [Chronic paroxysmal hemicrania. Treatment with indomethacin and diclofenac].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8530280" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A piroxicam derivative partly effective in chronic paroxysmal hemicrania and hemicrania continua.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15096232" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Seasonal episodic paroxysmal hemicrania responding to cyclooxygenase-2 inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15377317" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Trigeminal autonomic cephalgias and variants: clinical profile in Indian patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12716352" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Rofecoxib for the treatment of chronic paroxysmal hemicrania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10908918" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Responsiveness to celecoxib in chronic paroxysmal hemicrania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35277974" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Etoricoxib and celecoxib sensitive indomethacin-responsive headache disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15773821" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cluster headache and paroxysmal hemicrania: differential diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15196305" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Chronic paroxysmal hemicrania in early childhood: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2289232" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Single photon emission computed tomography (SPECT) with 99mTc-HMPAO (hexamethyl propylenamino oxime) in chronic paroxysmal hemicrania--a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8014035" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Adolescent chronic paroxysmal hemicrania responsive to verapamil monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16987158" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Treatment of SUNCT/SUNA, Paroxysmal Hemicrania, and Hemicrania Continua: An Update Including Single-Arm Meta-analyses</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1538227" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Episodic paroxysmal hemicrania responsive to calcium channel blockers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7843957" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Acetazolamide for the treatment of chronic paroxysmal hemicrania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17172571" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Paroxysmal hemicrania responding to topiramate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9728969" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : A case of chronic paroxysmal hemicrania responding to subcutaneous sumatriptan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28730562" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35833494" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Paroxysmal hemicrania in children and adolescents: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9127119" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Chronic paroxysmal hemicrania and hemicrania continua: anaesthetic blockades of pericranial nerves.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31084198" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Multiple cranial nerve blocks for the transitional treatment of chronic headaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16241981" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Seasonal, extratrigeminal, episodic paroxysmal hemicrania successfully treated with single suboccipital steroid injections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14756860" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cluster headache and the sympathetic nerve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28980700" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Occipital Nerve Stimulation for Medically Refractory Chronic Paroxysmal Hemicrania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28846758" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Noninvasive Vagus Nerve Stimulation for Treatment of Indomethacin-Sensitive Headaches.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30709897" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Non-invasive vagus nerve stimulation is beneficial in chronic paroxysmal hemicrania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19834392" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Successful treatment of chronic paroxysmal hemicrania with posterior hypothalamic stimulation: technical case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34163429" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The Promising Effect of Nerve Decompression in Trigeminal Autonomic Cephalalgias: Report of Case Series.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
